LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Admission of Innovative Medical Devices in respect of Congenital Heart Defect Occluder into Special Examination and Approval Procedure

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis.

The board of directors of the Company (the "**Board**") is pleased to announce that on 20 August 2025, the Company obtained formal written notice from the National Medical Products Administration ("**NMPA**") confirming the admission of Congenital Heart Defect Occluder (the "**Product**") into NMPA Special Examination and Approval Procedure for Innovative Medical Devices (藥監局創新醫療器械特別審查程序) (the "**Procedure**"). The Product is the 16th product of the Company having obtained admission to the Procedure.

Patent ductus arteriosus ("**PDA**") is one of the most common congenital heart diseases in clinical practice, accounting for approximately 12% to 15% of the incidence rate of all congenital heart diseases, and it may lead to serious complications such as pulmonary hypertension and heart failure if not treated in a timely manner. Transcatheter PDA occlusion procedure has gradually become the preferred treatment option for patients who meet the criteria due to its advantages of being minimally invasive, safe and with fast recovery. However, due to the existence of different structures and sizes of PDA, as well as the varying vascular conditions of patients, the adaptability of occlusion devices is faced with more challenges, making innovative devices that cater to multiple situations more necessary in clinical practice.

The Product is suitable for interventional treatment of congenital PDA, and is the first domestically produced PDA occluder with a full nitinol metal main body structure that can achieve bidirectional release of "antegrade approach" and "retrograde approach". The Product is woven from nitinol wires and designed with a self-expanding asymmetric double disc structure. Both the left and right discs can be connected to the delivery cable, allowing for flexible selection of either the "antegrade approach" or "retrograde approach" based on the patient's condition. Compared with the traditional antegrade approach, the retrograde approach is more convenient to operate, which not only shortens the procedural time, but also provides better treatment options for patients with venous system contraindications, allowing doctors to have more flexible solutions to face different types of PDA challenges.

The Group possesses independent intellectual property rights to the Product. At present, the registered clinical trials of the Product in China are steadily advancing, and the Company expects that there will be richer evidence-based medicine (EBM) evidence to further confirm the safety and effectiveness of the Product.

The Board believes that the admission of the Product into the Procedure will shorten the registration process of the Product, whereby expediting its launching process. It is expected that the launch of the Product will benefit PDA patients while enriching the Group's product portfolio and fostering the Group's development in medical devices.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 22 August 2025

As at the date of this announcement, the Board comprises Mr. XIE Yuehui, Mr. LIU Jianxiong and Ms. RUAN Xingmei being executive directors; Mr. JIANG Feng being non-executive director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive directors.